ARP-1536 Retinopathy/Nephropathy

Same target, different indications: ARP-1536

ARP-1536 is a humanized monoclonal antibody that targets the extracellular domain of VE-PTP. In preclinical models, ARP-1536 activated the Tie2 receptor in a dose-dependent manner with a pre-clinical efficacy profile similar to AKB-9778.

Our TIME2 trial with subcutaneous AKB-9778 was the first to show the promise of combining Tie2 activation and VEGF inhibition in patients with DME.  Based on TIME2 and promising preclinical data, intravitreal ARP-1536 is in preclinical development as an adjunct to anti-VEGF therapy for DME and wAMD.

Based on the long half-life of monoclonal antibodies, ARP-1536 has the potential to be administered systemically once monthly or bimonthly to treat diabetic complications. ARP-1536 is being developed as a potential follow on product in a more convenient dose form for diabetic nephropathy.

Combining the Tie2 activating properties of ARP-1536 with VEGF neutralization in a bispecific biologic is in early preclinical development for DME and wAMD by intravitreal administration and for cancer by systemic (intravenous or subcutaneous) administration.

Click here to view publications on ARP-1536